Subscribe
Healthcare

FDA approves world’s first CRISPR gene-editing drug for sickle cell disease

By Gabrielle M. Etzel
Published
Add Washington Examiner on Google
FDA approves world’s first CRISPR gene-editing drug for sickle cell disease

The Food and Drug Administration has approved the world’s first medicine employing CRISPR gene-editing technology to treat sickle cell disease, giving thousands new hope to treat the painful disease.

Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.

Tag:

FDA Pharmaceutical Industry